Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease

Journal of Neurochemistry

Volumn 115, Issue 1, 2010, Pages 153-167

  Del Toro, Daniel ^a,b,c   Xifró, Xavier ^a,b,c,e   Pol, Albert ^c,d   Humbert, Sandrine ^f   Saudou, Frédéric ^f   Canals, Josep M ^a,b,c   Alberch, Jordi ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e UNIVERSITY OF GIRONA   (Spain)

^f CNRS   (France)

Author keywords

caveolin; cholesterol; GM1; huntingtin; lipid rafts; simvastatin

Indexed keywords

BETA CYCLODEXTRIN; CAVEOLIN 1; CHOLESTEROL; GANGLIOSIDE GM1; HUNTINGTIN; MUTANT PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SIMVASTATIN; AMINO ACID RECEPTOR STIMULATING AGENT; BETA CYCLODEXTRIN DERIVATIVE; DNA; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; HUNTINGTON PROTEIN, MOUSE; HYPOCHOLESTEROLEMIC AGENT; N METHYLASPARTIC ACID; NERVE PROTEIN; NUCLEAR PROTEIN; TRIACYLGLYCEROL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPIFLUORESCENCE MICROSCOPE; EXCITOTOXICITY; HUNTINGTON CHOREA; LIPID STORAGE; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ANIMAL; BRAIN; CELL CULTURE; CELL MEMBRANE; CELL SURVIVAL; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; HOMEOSTASIS; HUMAN; METABOLISM; NEOSTRIATUM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

MURINAE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BETA-CYCLODEXTRINS; BRAIN; CAVEOLIN 1; CELL MEMBRANE; CELL SURVIVAL; CELLS, CULTURED; CHOLESTEROL; DNA; EXCITATORY AMINO ACID AGONISTS; FLUORESCENT ANTIBODY TECHNIQUE; HOMEOSTASIS; HUMANS; HUNTINGTON DISEASE; INDICATORS AND REAGENTS; MEMBRANE MICRODOMAINS; MICE; MICE, TRANSGENIC; N-METHYLASPARTATE; NEOSTRIATUM; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; SIMVASTATIN; TRANSFECTION; TRIGLYCERIDES;

EID: 77956577915     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06912.x     Document Type: Article

References (54)

1. Arispe N. Doh M. (2002) Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. FASEB J. 16, 1526 1536.
2. Burns M. P., Igbavboa U., Wang L., Wood W. G. Duff K. (2006) Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. Neuromol. Med. 8, 319 328.
3. Dietschy J. M. Turley S. D. (2004) Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375 1397.
4. Distl R., Treiber-Held S., Albert F., Meske V., Harzer K. Ohm T. G. (2003) Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. J. Pathol. 200, 104 111.
5. Fan J., Cowan C. M., Zhang L. Y., Hayden M. R. Raymond L. A. (2009) Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J. Neurosci. 29, 10928 10938.
6. Fielding C. J., Bist A. Fielding P. E. (1997) Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc. Natl Acad. Sci. USA 94, 3753 3758.
7. Frank P. G., Galbiati F., Volonte D., Razani B., Cohen D. E., Marcel Y. L. Lisanti M. P. (2001) Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins. Am. J. Physiol. Cell Physiol. 280, C1204 C1214.
8. Frank P. G., Marcel Y. L., Connelly M. A., Lublin D. M., Franklin V., Williams D. L. Lisanti M. P. (2002) Stabilization of caveolin-1 by cellular cholesterol and scavenger receptor class B type I. Biochemistry 41, 11931 11940.
9. Frank P. G., Cheung M. W., Pavlides S., Llaverias G., Park D. S. Lisanti M. P. (2006) Caveolin-1 and regulation of cellular cholesterol homeostasis. Am. J. Physiol. Heart Circ. Physiol. 291, H677 H686.
10. Gaus K., Le L. S., Balasubramanian N. Schwartz M. A. (2006a) Integrin-mediated adhesion regulates membrane order. J. Cell Biol. 174, 725 734.
11. Gaus K., Zech T. Harder T. (2006b) Visualizing membrane microdomains by Laurdan 2-photon microscopy. Mol. Membr. Biol. 23, 41 48.
12. Gauthier L. R., Charrin B. C., Borrell-Pages M. et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127 138.
13. Ghittoni R., Patrussi L., Pirozzi K., Pellegrini M., Lazzerini P. E., Capecchi P. L., Pasini F. L. Baldari C. T. (2005) Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 19, 605 607.
14. Ghosh A., Roy A., Matras J., Brahmachari S., Gendelman H. E. Pahan K. (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 29, 13543 13556.
15. Giralt A., Rodrigo T., Martin E. D., Gonzalez J. R., Mila M., Cena V., Dierssen M., Canals J. M. Alberch J. (2009) Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience 158, 1234 1250.
16. Gratacos E., Checa N., Perez-Navarro E. Alberch J. (2001) Brain-derived neurotrophic factor (BDNF) mediates bone morphogenetic protein-2 (BMP-2) effects on cultured striatal neurones. J. Neurochem. 79, 747 755.
17. Greenspan P., Mayer E. P. Fowler S. D. (1985) Nile red: a selective fluorescent stain for intracellular lipid droplets. J. Cell Biol. 100, 965 973.
18. Hailstones D., Sleer L. S., Parton R. G. Stanley K. K. (1998) Regulation of caveolin and caveolae by cholesterol in MDCK cells. J. Lipid Res. 39, 369 379.
19. Head B. P., Patel H. H., Tsutsumi Y. M., Hu Y., Mejia T., Mora R. C., Insel P. A., Roth D. M., Drummond J. C. Patel P. M. (2008) Caveolin-1 expression is essential for N-methyl-D-aspartate receptor-mediated Src and extracellular signal-regulated kinase 1/2 activation and protection of primary neurons from ischemic cell death. FASEB J. 22, 828 840.
20. Holleran B. J., Barbar E., Payet M. D. Dupuis G. (2003) Differential recruitment of alpha2beta1 and alpha4beta1 integrins to lipid rafts in Jurkat T lymphocytes exposed to collagen type IV and fibronectin. J. Leukoc. Biol. 73, 243 252.
21. Ingelmo-Torres M., Gaus K., Herms A., Gonzalez-Moreno E., Kassan A., Bosch M., Grewal T., Tebar F., Enrich C. Pol A. (2009) Triton X-100 promotes a cholesterol-dependent condensation of the plasma membrane. Biochem. J. 420, 373 381.
22. Johnson-Anuna L. N., Eckert G. P., Keller J. H., Igbavboa U., Franke C., Fechner T., Schubert-Zsilavecz M., Karas M., Muller W. E. Wood W. G. (2005) Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J. Pharmacol. Exp. Ther. 312, 786 793.
23. Kremer B., Goldberg P., Andrew S. E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A. Almqvist E. (1994) A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 330, 1401 1406.
24. Leoni V., Mariotti C., Tabrizi S. J. et al. (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131, 2851 2859.
25. Nabi I. R. Le P. U. (2003) Caveolae/raft-dependent endocytosis. J. Cell Biol. 161, 673 677.
26. Nichols B. J. (2003) GM1-containing lipid rafts are depleted within clathrin-coated pits. Curr. Biol. 13, 686 690.
27. Paolisso G., Sgambato S., De R. S., Gambardella A., Verza M., Varricchio M. D'Onofrio F. (1991) Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur. J. Clin. Pharmacol. 40, 27 31.
28. Perez-Navarro E., Canals J. M., Gines S. Alberch J. (2006) Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease. Histol. Histopathol. 21, 1217 1232.
29. Ponce J., de la Ossa N. P., Hurtado O., Millan M., Arenillas J. F., Davalos A. Gasull T. (2008) Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke 39, 1269 1275.
30. Reiner A., Albin R. L., Anderson K. D., D'Amato C. J., Penney J. B. Young A. B. (1988) Differential loss of striatal projection neurons in Huntington disease. Proc. Natl Acad. Sci. USA 85, 5733 5737.
31. Saudou F., Finkbeiner S., Devys D. Greenberg M. E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55 66.
32. Silvius J. R. (2003) Role of cholesterol in lipid raft formation: lessons from lipid model systems. Biochim. Biophys. Acta 1610, 174 183.
33. Simons K. Ehehalt R. (2002) Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110, 597 603.
34. Sipione S., Rigamonti D., Valenza M., Zuccato C., Conti L., Pritchard J., Kooperberg C., Olson J. M. Cattaneo E. (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet. 11, 1953 1965.
35. Thelen K. M., Rentsch K. M., Gutteck U., Heverin M., Olin M., Andersson U., von E. A., Bjorkhem I. Lutjohann D. (2006) Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 316, 1146 1152.
36. del Toro D., Alberch J., Lazaro-Dieguez F., Martin-Ibanez R., Xifro X., Egea G. Canals J. M. (2009) Mutant huntingtin impairs post-Golgi trafficking to lysosomes by delocalizing optineurin/rab8 complex from the Golgi apparatus. Mol. Biol. Cell 20, 1478 1492.
37. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V. C., Sharp A. H., Persichetti F., Cattaneo E. MacDonald M. E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799 2809.
38. Trushina E., Singh R. D., Dyer R. B., Cao S., Shah V. H., Parton R. G., Pagano R. E. McMurray C. T. (2006) Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum. Mol. Genet. 15, 3578 3591.
39. Vainio S., Bykov I., Hermansson M., Jokitalo E., Somerharju P. Ikonen E. (2005) Defective insulin receptor activation and altered lipid rafts in Niemann-Pick type C disease hepatocytes. Biochem. J. 391, 465 472.
40. Valenza M. Cattaneo E. (2006) Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list? Prog. Neurobiol. 80, 165 176.
41. Valenza M., Rigamonti D., Goffredo D. et al. (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 25, 9932 9939.
42. Valenza M., Carroll J. B., Leoni V., Bertram L. N., Bjorkhem I., Singaraja R. R., Di D. S., Lutjohann D., Hayden M. R. Cattaneo E. (2007a) Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum. Mol. Genet. 16, 2187 2198.
43. Valenza M., Leoni V., Tarditi A., Mariotti C., Bjorkhem I., Di D. S. Cattaneo E. (2007b) Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 28, 133 142.
44. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D. Richardson Jr. E. P. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559 577.
45. Wahner A. D., Bronstein J. M., Bordelon Y. M. Ritz B. (2008) Statin use and the risk of Parkinson disease. Neurology 70, 1418 1422.
46. Wang X. Q. Paller A. S. (2006) Lipid rafts: membrane triage centers. J. Invest. Dermatol. 126, 951 953.
47. Wheeler V. C., Auerbach W., White J. K. et al. (1999) Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115 122.
48. Wolozin B., Kellman W., Ruosseau P., Celesia G. G. Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439 1443.
49. Wolozin B., Wang S. W., Li N. C., Lee A., Lee T. A. Kazis L. E. (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 5, 20.
50. Xie C., Lund E. G., Turley S. D., Russell D. W. Dietschy J. M. (2003) Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J. Lipid Res. 44, 1780 1789.
51. Xifro X., Garcia-Martinez J. M., Del T. D., Alberch J. Perez-Navarro E. (2008) Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J. Neurochem. 105, 1596 1612.
52. Zajchowski L. D. Robbins S. M. (2002) Lipid rafts and little caves. Compartmentalized signalling in membrane microdomains. Eur. J. Biochem. 269, 737 752.
53. Zeron M. M., Hansson O., Chen N., Wellington C. L., Leavitt B. R., Brundin P., Hayden M. R. Raymond L. A. (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849 860.
54. Zervas M., Dobrenis K. Walkley S. U. (2001) Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J. Neuropathol. Exp. Neurol. 60, 49 64.